Knome Personal Genomics Service Expands to Include 93,000 Rare Mutations from the Human Gene Mutation Database Distributed by BI

Knome Personal Genomics Service Expands to Include 93,000 Rare Mutations from the Human Gene Mutation Database Distributed by BIOBASE.

CAMBRIDGE, Mass. and WOLFENBÜTTEL, Germany--(BUSINESS WIRE)--Knome, a recognized pioneer in the personal genomics industry, announced today that it is incorporating information from The Human Gene Mutation Database (HGMD - Cardiff University, UK) distributed by BIOBASE, into its genome interpretation services. With over 93,000 mutations and disease-related polymorphisms in more than 3,500 genes, HGMD is one of the world's most comprehensive databases of medically relevant genetic variation. Typically used by large research institutions and pharmaceutical companies, this is the first time the genomic data in the HGMD is being made available as part of a consumer offering.


Business Wire - (Graphic: Business Wire).  View Multimedia Gallery ...
Under the agreement, Knome will include HGMD in its KnomeXplorerTM genome browser software, and in its genome interpretation update service. The data will be continuously updated with the latest findings and distributed to Knome's clients, giving them direct access to the most up-to-date information on a real-time basis. "Incorporating HGMD into our service will significantly expand the dataset used in our core analysis and enhance the content we provide to clients in our update service," said Jorge Conde, CEO of Knome.

Unlike entry-level consumer genomic services that limit their focus to variants that are common in the general population, Knome informs its clients of even very rare variants that they carry, many of which are thought to be elusive causes of relatively common diseases, such as colorectal cancer and diabetes, that can dramatically affect health and quality of life. Every person likely carries many such variants, each one of which may -- due to its potentially debilitating effects in carriers or their children -- remain too rare to be included in entry-level SNP-chip based services. For example, the incorporation of HGMD adds an additional 1,698 mutations in 76 genes for colorectal cancer, and 1,435 mutations in 110 genes for diabetes, into Knome's automated interpretation software.

Michael Tysiak, CEO of BIOBASE said, "Combined with their sequencing capabilities and interpretation services, the addition of our rare mutation database will enable Knome to provide even deeper insight into each client's genetic profile and deliver greater customer value."

Financial terms and conditions of the agreement were not disclosed.

About BIOBASE

BIOBASE (www.biobase-international.com), based in Wolfenbüttel (Germany), with offices in Beverly, MA (USA), Bangalore (India) and Yokohama (Japan), is a leading provider of expertly curated biological databases for the life science industry. BIOBASE's product portfolio, referred to as the BIOBASE Knowledge LibraryTM (BKL), includes industry standards such as TRANSFAC® , PROTEOME YPDTM and HumanPSDTM databases. In combination with BIOBASE's powerful systems biology software, ExPlainTM, the BKL can be used to analyze complex regulatory networks and identify key molecules linked to human disease. BIOBASE also provides a growing collection of third-party databases including BRENDA® and the Human Gene Mutation Database (HGMD ). More than 600 customers now license BIOBASE databases worldwide.

About Knome, Inc.

Knome is a leading personal genomics company focused on providing state-of-the-art sequencing and interpretation solutions. Led by prominent geneticists, clinicians and bioinformaticians, Knome is the first company to offer complete genome sequencing and interpretation services to private individuals. To date, Knome has been responsible for sequencing and interpreting more human genomes than any other company in the world. Knome empowers its clients to understand and control their genomic information in a manner that is both anonymous and secure. For more information, please visit www.knome.com.

Knome, KnomeSELECT and KnomeCOMPLETE are trademarks of Knome, Inc.

Suggested Articles

Insitro picked up $143 million to build out its technology, pursue new targets and advance treatments for genetically defined patient groups.

Generation Bio filed for a $215 million IPO to advance a pair of gene therapies for liver disease and push one of them into the clinic.

The IPO will push Avidity's lead muscle disorder program through IND-enabling studies and into the clinic in 2021.